Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Earnings
Manufacturing
Catalent reports upbeat Q4 results as it awaits review of sale
Catalent, which is waiting on a review by the Federal Trade Commission of its $16.5 billion sale to Novo, reported upbeat fourth-quarter earnings.
Joseph Keenan
Aug 30, 2024 9:30am
Stada charts strong first half of 2024 as owners weigh options
Aug 28, 2024 4:25pm
21 of biopharma industry's top 25 saw revenue increases in Q2
Aug 22, 2024 1:16pm
WuXi Bio continues to snag new projects despite BIOSECURE fears
Aug 22, 2024 9:58am
Tarsus is building momentum thanks to its Xdemvy eye drug launch
Aug 14, 2024 3:32pm
Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia
Aug 14, 2024 12:07pm
